J&J’s medtech business slows again in Q3

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 13 Oct, 16:34 UTC

For the second straight quarter, the cardiovascular unit experienced slower sales growth due to ongoing struggles in the Abiomed business.